602results about How to "Improve side effects" patented technology

Methods and systems for treating patients requiring tissue ablation for volumetric tissue reduction rely on the injection of ethanol and other tissue-ablating agents into the perivascular space surrounding body lumens, particularly blood vessels or vessels of the alimentary canal, reproductive system and urinary tract. Injection of tissue-ablating agents is intended treat conditions such as hypertrophic cardiomyopathy, benign and malignant tumors, benign prostatic hyperplasia, and uterine fibroids, for example. Injection may be achieved using intravascular catheters which advance needles radially outward from a body vessel lumen or by transmyocardial injection from an epicardial or endocardial surface of the heart.

The present invention provides oral dosage forms and compositions for administering antineoplastic agents, such as irinotecan, etoposide, paclitaxel, doxorubicin and vincristine, whose oral effectiveness is limited by pre-systemic and systemic deactivation in the GI tract. Gelling of the gastric retention vehicle composition, and in the case of solid forms concomitant expansion of the composition, retains the antineoplastic drug in the patient's stomach, minimizing pre-systemic and / or systemic deactivation of the drug.

A polycyclic guanine phosphodiesterase V inhibitor having the formula (I.1) or (II.1), with the variables defined herein, which is useful for treating sexual dysfunction and other physiological disorders: A representative example is:

Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, are disclosed. Methods of treatment using the compositions are also disclosed. The material to be eliminated can include residual active antibiotics, metabolites, bacterial or other toxins, and drugs which cause side effects in the gastrointestinal tract. The adsorbents can be formulated in capsules, tablets or any acceptable pharmaceutical composition, and are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. The programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and / or colon.

A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg / ml to about 1052 pg / ml is attained, and thereafter maintaining the administration of buprenorphine for at least an addition two-day dosing interval in accordance with substantially zero order kinetics, such that the patients experience analgesia throughout the at least two-day additional dosing interval.

The present invention relates to compounds of the formulaand pharmaceutically acceptable salts, solvates or tautomers thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds, and the uses of such compounds, in particular for the treatment of pain.

The invention provides a highly stable lithium nickel cobalt aluminate positive electrode material and its preparation method. The characteristic chemical formula of the lithium nickel cobalt aluminate material is LinNi1-x-yCoxAlyO2.mLiMaOb, wherein n is not less than 0.95 and not more than 1.15, x is more than 0.00 and less than 0.30, y is not less than 0.01 and not more than 0.10, m is more than 0.00 and less than 0.05, a is more than 0.0 and less than 3.0, b is a valence matching coefficient, and b is (M valence * a +1) / 2. The morphology of the material is a spheroidic secondary particle structure formed by a primary particle, the average particle size of the primary particle is 0.10-2.5mum, and the average particle size of the secondary particle is 3.0-20.0mum. LiMaOb is a composite oxide lithium ion conductor coating and is uniformly distributed on the surface of the primary and secondary particle, so the removal and embedding of lithium ions in the battery charge and discharge process are promoted, and the side reactions of the lithium nickel cobalt aluminate material and an electrolyte can be inhibited. The above lithium ion battery positive electrode material has the advantages of high energy, high safety and long cycle life.

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer.

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.

The invention discloses a rose enzyme and a preparation technology of the rose enzyme. The rose enzyme comprises the following components by weight ratio: 80-100kg of water, 25-30kg of rose, 8-10kg of brown sugar or honey and 5-8kg of traditional Chinese medicine auxiliary material; the preparation technology of the rose enzyme utilizes pure natural rose petals and the traditional Chinese medicine auxiliary material to produce the enzyme by natural fermentation; the preparation method of the rose enzyme is simple, easy to operate and short in fermentation period; the rose enzyme is good in mouth feel, can be easily absorbed by a human body, is free from toxin, harm and side effects for the human body, does not contain any additive, preservative and hormone, and enables a user not to worry about getting fat and having dependence on the product; the food is high in safety, the nutrient content of the rose enzyme is not reduced, and the rose enzyme also has good functions of health care and treatment for gynecological diseases; the rose enzyme is better in health care effect, can be eaten for a long time and is an excellent health care product for women; the rose enzyme not only can be produced on a large scale, but also can be widely used in families.

The invention relates to a composition with the plant estrogen-like effects, and the composition is prepared by the following pharmaceutical raw materials by weight percentage: 12-64 percent eucommia bark and 6-38 percent malaytea scurfpea fruit. The traditional Chinese medicine composition has the plant estrogen-like effects and can bi-directionally regulate the estrogen level of human body, delay the arrival of menopause and be applicable to improving the perimenopausal syndrome of women: menstrual disorders, vasomotor symptoms (flushes and hot flushes), mental and neurological disorders (depression, anxiety, excitability and insomnia), cardiovascular and cerebrovascular symptoms (hypertension, hyperlipidemia, heart palpitations, atherosclerosis, coronary heart disease, senile dementia, and the like), bone and joint symptoms (osteoporosis, arthralgia, and the like), symptoms of urogenital tract and other diseases.

The invention discloses a compound medicine for treating anaphylactic rhinitis-asthma syndrome and a preparation method and application thereof. The compound medicine comprises, by weight, of 60-300 parts of astragalus mongholicus, 20-100 parts of ephedra, 20-200 parts of divaricate saposhnikovia root, 20-200 parts of trichosanthes peel, 20-200 parts of allium macrostemon, 20-200 parts of rhizoma pinellinae praeparata, 12-120 parts of rhizoma zingiberis, 20-200 parts of almond, 20-200 parts of bighead atractylodes rhizome, 20-200 parts of cassia twig, 20-200 parts of poria cocos, 30-300 parts of radix paeoniae alba, 30-300 parts of lumbricus and 30-300 parts of honey-fried licorice root. The compound medicine for treating the anaphylactic rhinitis-asthma syndrome has the advantages of being good in curative effect, short in course of treatment, thorough in curative effect, free of side effect and the like. The preparation method for preparing the compound medicine for treating the anaphylactic rhinitis-asthma syndrome is simple, rapid, high in efficiency and easy to operate. Prepared mixture, troche, capsules, pellets and the like are convenient to carry and take.